外基因携带的FER抑制剂通过调节AJUBA/Hippo轴抑制扩散型大B细胞淋巴瘤的进展
Jiarui Liu1, Yang Han1, Tiange Lu1
1Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China.
NPJ precision oncology
|July 24, 2025
概括
氨酸激酶FER在扩散性大B细胞淋巴瘤 (DLBCL) 中被上调,推动瘤生长和化学抵抗. 抑制FER,特别是通过外体递送的E260,为DLBCL提供了一个有前途的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 细胞内氨酸激酶FER在各种癌症中普遍存在.
- 它在扩散性大B细胞淋巴瘤 (DLBCL) 中的作用和调节机制尚不清楚.
- 了解FER在DLBCL中的功能对于开发向疗法至关重要.
研究的目的:
- 调查FER在DLBCL病原和化学抵抗中的作用.
- 评估DLBCL中FER抑制的治疗潜力.
- 探索循环外体FER的诊断和预后价值.
主要方法:
- 在DLBCL患者样本中分析FER表达水平.
- 使用FER抑制剂E260在DLBCL细胞系上的体外研究.
- 使用外体体封装E260和化疗药物的联合治疗的评估.
- 研究涉及Hippo信号通路组件的分子机制 (AJUBA,YAP).
- 在DLBCL患者中检测循环外体FER.
主要成果:
- 在DLBCL中,FER表达被上调,与糟糕的结局和增加瘤发生有关.
- 使用E260抑制FER抑制DLBCL细胞增殖和瘤生长.
- 与外体E260和化疗药物的联合治疗表明,与单一治疗相比,瘤抑制能力提高.
- 通过抑制AJUBA,E260治疗恢复了Hippo的信号活动,导致细胞质中YAP的封存.
- 循环外体FER水平被确定为DLBCL诊断和进展的潜在生物标志物.
结论:
- FER是DLBCL进展和化疗抵抗的重要驱动因素,使其成为潜在的治疗点.
- 用像E260这样的抑制剂向FER,特别是通过外体传递时,显示了DLBCL的治疗前景.
- 外体FER具有作为DLBCL诊断和监测治疗反应的非侵入性生物标志物的潜力.
相关概念视频
01:15Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K
01:15Transcytosis of IgG
2.9K
Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
2.9K
01:17The Extrinsic Apoptotic Pathway
6.6K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.6K
01:01Regulation of Hematopoietic Stem Cells
3.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.3K
01:22PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271